REFERENCES
- Barnard, K. D., L. Dent, and A. Cook. 2010. A systematic review of models to predict recruitment to multicentre clinical trials. BMC Medical Research Methodology 10:63. doi:10.1186/1471-2288-10-63.
- Hartmann, J., M. Schüßler-Lenz, A. Bondanza, and C. J. Buchholz. 2017. Clinical development of CAR T cells—Challenges and opportunities in translating innovative treatment concepts. EMBO Molecular Medicine 9:1183–97. doi:10.15252/emmm.201607485.
- Huang, L., N. Wang, C. Li, et al. 2017. Sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells for adult patients with refractory/relapsed B-cell acute lymphoblastic leukemia. Presented at American Society of Hematology Annual Meeting, Atlanta, GA, December 9–12. Available at: https://ash.confex.com/ash/2017/webprogram/Paper103148.html (accessed February 19, 2018).
- Jecker, N. S., A. G. Wightman, A. R. Rosenberg, and D. S. Diekema. 2018. Ethical guidance for selecting clinical trials to receive limited space in an immunotherapy production facility. American Journal of Bioethics 18 (4):56–64.
- Levine, B. L., J. Miskin, K. Wonnacott, and C. Keir. 2017. Global manufacturing of CAR T cell therapy. Molecular Therapy—Methods & Clinical Development 4:92–101. doi:10.1016/j.omtm.2016.12.006.
- Maus, M. V., A. R. Haas, G. L. Beatty, et al. 2013. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunology Research 1:26–31. doi:10.1158/2326-6066.CIR-13-0006.
- NSF Engineering Research Center for Cell Manufacturing Technologies. 2018. CMaT: NSF Engineering Research Center for Cell Manufacturing Technologies. Available at: http://cellmanufacturingusa.org (accessed February 1, 2018).
- U.S. Food and Drug Administration. 2017. FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss. December 19. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnounceme-nts/ucm589467.htm (accessed February 16, 2018).
- Vormittag, P., R. Gunn, S. Ghorashian, and F. S. Veraitch. 2018. A guide to manufacturing CAR T cell therapies. Current Opinion in Biotechnology 53:164–81. doi:10.1016/j.copbio.2018.01.025.